Renal Cancer Drugs Market by therapy (targeted therapy, chemotherapy, and immunotherapy), drug class (anti-angiogenesis, mTOR inhibitors, interleukin, and immune checkpoint inhibitors), indication (renal cell carcinoma, urothelial carcinoma, and others), distribution channel (hospitals, specialty & retail pharmacies and others), and region (North America, Europe, Asia Pacific and Rest of the World (RoW) which includes Latin America and Middle East & Africa) – global forecasts to 2027
The renal cancer drugs market is projected to reach USD 8 billion by 2027 from USD 6 billion in 2022, at a CAGR of 6% during the forecast period.
To know about the assumptions considered for the study, Request for Free Sample Report
Renal cancer commonly known as kidney cancer originates in the lining of the proximal convoluted tubule of the kidney. Renal cancer is caused by Von Hippel-Lindau (VHL) syndrome, obesity, smoking, high blood pressure, long-term dialysis, and occupational exposure (for example asbestos workers). The symptoms of renal cancer include a lump or mass in the abdomen or side, blood in the urine, weight loss, fever, and lethargy. Several drugs for the treatment of renal cancer are currently available in the market.
The global renal cancer drugs market is likely to show significant growth during the forecast period. This is attributed to the rising incidences of renal cancer, increasing geriatric population, and approval of novel molecules to develop drugs. However, high prices of branded drugs to treat cancer and rising preference for generic drugs are expected to restrain the market for renal cancer drugs market.
The renal cancer drugs market is segmented into five broad categories: by therapy, by drug class, by indication, by distribution channel, and by region. Based on therapy, the market is divided into targeted therapy, chemotherapy, and immunotherapy. The renal cancer drugs class is categorized into anti-angiogenesis, mTOR inhibitors, interleukin, and immune checkpoint inhibitors. Based on indication, the market is segmented into renal cell carcinoma, urothelial carcinoma, and others.
To know about the assumptions considered for the study, download the pdf brochure
Based on distribution channel, the renal cancer drugs market is segmented into hospitals, specialty & retail pharmacies and others. On the basis of region, the renal cancer drugs market is segmented into North America, Europe, Asia Pacific and Rest of the World (RoW) which includes Latin America and Middle East & Africa.
The major players in the renal cancer drugs market are Active Biotech AB (Sweden), Amgen, Inc. (US), Bayer AG (Germany), Cipla Limited (India), F. Hoffmann-La Roche AG (Switzerland), Genentech, Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Onyx Pharmaceuticals, Inc. (US), Pfizer, Inc. (US).
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKET COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.2.1 KEY INDUSTRY INSIGHTS
2.2 MARKET SIZE ESTIMATION
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.4 PRICING ANALYSIS
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 PATENT ANALYSIS
5.8 KEY CONFERENCES AND EVENTS IN 2022-2023
5.9 REGULATORY ANALYSIS
5.10 PORTER’S FIVE FORCES ANALYSIS
5.11 KEY STAKEHOLDER AND BUYING CRITERIA
6 RENAL CANCER DRUGS MARKET, BY THERAPY, 2020-2027 (USD MILLION)
6.1 INTRODUCTION
6.2 TARGETED THERAPY
6.3 CHEMOTHERAPY
6.4 IMMUNOTHERAPY
7 RENAL CANCER DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
7.1 INTRODUCTION
7.2 ANTI-ANGIOGENESIS
7.3 MTOR INHIBITORS
7.4 INTERLEUKIN
7.5 IMMUNE CHECKPOINT INHIBITORS
8 RENAL CANCER DRUGS MARKET, BY INDICATION, 2020-2027 (USD MILLION)
8.1 INTRODUCTION
8.2 RENAL CELL CARCINOMA
8.3 UROTHELIAL CARCINOMA
8.4 OTHERS
8 RENAL CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
8.1 INTRODUCTION
8.2 HOSPITAL
8.3 SPECIALTY & RETAIL PHARMACIES
8.4 OTHERS
9 RENAL CANCER DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE
9.3.3 UK
9.3.4 ITALY
9.3.5 SPAIN
9.3.6 ROE
9.4 ASIA PACIFIC
9.4.1 JAPAN
9.4.2 CHINA
9.4.3 INDIA
9.4.4 REST OF APAC
9.5 REST OF THE WORLD (ROW)
9.5.1 LATIN AMERICA
9.5.2 MIDDLE EAST & AFRICA
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
10.4 MARKET SHARE ANALYSIS, 2021
10.5 COMPANY EVALUATION QUADRANT
10.6 COMPANY EVALUATION QUADRANT – SME/START-UPS
10.7 COMPANY GEOGRAPHIC FOOTPRINT
10.8 COMPETITIVE SCENARIO
11 COMPANY PROFILES
(The details on business overview, financial information, products/services portfolio, recent developments, MarketsandMarkets view will be provided)*
11.1 ACTIVE BIOTECH AB
11.2 AMGEN
11.3 BAYER AG
11.4 CIPLA LIMITED
11.5 F. HOFFMANN-LA ROCHE AG
11.6 GENENTECH INC.
11.7 GLAXOSMITHKLINE PLC
11.8 NOVARTIS AG
11.9 ONYX PHARMACEUTICALS INC.
11.10 PFIZER INC.
* Details on business overview, financial information, products/services portfolio, recent developments, MarketsandMarkets view might not be captured in case of unlisted companies.
12 APPENDIX
12.1 INSIGHTS FROM INDUSTRY EXPERTS
12.2 DISCUSSION GUIDE
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
12.5 AVAILABLE CUSTOMIZATIONS
12.6 RELATED REPORTS
12.7 AUTHOR DETAILS
Growth opportunities and latent adjacency in Renal Cancer Drugs Market